ExpreS2ion Biotech Holding

ExpreS2ion is expected to release its Q1 2026 interim report on 28 May 2026. Later the same day at 10.00, ExpreS2ion's CEO Bent U. Frandsen and CFO Keith Alexander will present the results and answer questions in a live online event.

New Phase Ia clinical data from the University of Oxford's BIO-002 study on Malaria further validates the Expres2ion platform

ExpreS2ion Biotech has today published the final terms for its previously announced fully pre-emptive rights issue with gross proceeds of approximately SEK 53 million before transaction costs.

ExpreS2ion today reported updated Phase I data showing consistent immune responses across dose levels. The independent DSMB recommends escalation to the 450 µg dose level and expansion of the 150 µg cohort, with no safety concerns identified.

ExpreS2ion has announced its intention to carry out a rights issue of units of approximately SEK 53 million before transaction costs, with each unit consisting of one new share and one TO 13 warrant exercisable in September 2026 at 70% of the prevailing VWAP. The issue is secured to approximately 60% through subscription and guarantee commitments, with an extraordinary general meeting scheduled for 1 April 2026, subscription period expected 16–30 April, and final terms to be set no later than 6 April based on a TERP discount of at least 35%. Proceeds are primarily earmarked to complete the Phase I dose-escalation (expected mid-2026) and expansion cohort (late 2026) of lead candidate ES2B-C001, its HER2-targeted breast cancer vaccine.